Haemonetics Corporation /
OpSens, Inc.
Haemonetics to acquire OpSens in an all-cash deal




What happened
Haemonetics Corporation agreed to acquire all outstanding shares of OpSens, Inc. for CAD $2.90 per share in cash. The transaction represents a fully diluted equity value of approximately USD $253 million.
OpSens offers optical technology primarily for use in interventional cardiology. Closing is subject to shareholder, court and regulatory approvals and other customary conditions.
The source
Everything on this page comes from the source below.
Haemonetics to acquire OpSens in an all-cash deal
This document is the source for the companies, stage, figure and people on this page.
Original filingUnlock with ProTimeline
Every date the source states, in order. Anything marked ahead is a target the source gives, not something that has happened.
Published by the source
The source this page is built from.
The same firms, in other deals
The firms' deal history and connections across other deals.
These firms' full profiles are part of Pro.
Request accessAlready invited? Sign in
Carrywatch Pro is by invitation. An invite lets you buy Pro.
By email · Weekly